caffeine has been researched along with Atherosclerotic Parkinsonism in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " After three weeks as a recovery period, 6-OHDA-induced bradykinesia and balance disturbances were assessed by using beam traversal test 10, 30 and 60 minutes after intraperitoneal injections of the drugs (caffeine, SCH58261)." | 3.83 | Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat. ( Mahmoudi, J; Reyhani-Rad, S, 2016) |
| "A dose-response meta-analysis was carried out between Parkinson's disease (PD) risk, and coffee, tea and caffeine consumption." | 2.50 | Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. ( Li, S; Qi, H, 2014) |
| "A reduced risk for Parkinson's disease (PD) among cigarette smokers has been observed consistently during the past 30 years." | 1.31 | Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. ( Checkoway, H; Franklin, GM; Longstreth, WT; Powers, K; Smith-Weller, T; Swanson, PD, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (75.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qi, H | 1 |
| Li, S | 1 |
| Reyhani-Rad, S | 1 |
| Mahmoudi, J | 1 |
| Song, L | 1 |
| Kong, M | 1 |
| Ma, Y | 1 |
| Ba, M | 1 |
| Liu, Z | 1 |
| Kalda, A | 1 |
| Herm, L | 1 |
| Rinken, A | 1 |
| Zharkovsky, A | 1 |
| Chen, JF | 3 |
| Xu, K | 1 |
| Xu, YH | 1 |
| Schwarzschild, MA | 2 |
| Yadav, S | 1 |
| Gupta, SP | 1 |
| Srivastava, G | 1 |
| Srivastava, PK | 1 |
| Singh, MP | 1 |
| Morelli, M | 1 |
| Coccurello, R | 1 |
| Breysse, N | 1 |
| Amalric, M | 1 |
| Joghataie, MT | 1 |
| Roghani, M | 1 |
| Negahdar, F | 1 |
| Hashemi, L | 1 |
| Bové, J | 1 |
| Serrats, J | 1 |
| Mengod, G | 1 |
| Cortés, R | 1 |
| Tolosa, E | 1 |
| Marin, C | 1 |
| Yu, L | 1 |
| Bata-García, JL | 1 |
| Villanueva-Toledo, J | 1 |
| Gutiérrez-Ospina, G | 1 |
| Alvarez-Cervera, FJ | 1 |
| Heredia-López, FJ | 1 |
| Góngora-Alfaro, JL | 1 |
| Sääksjärvi, K | 1 |
| Knekt, P | 1 |
| Rissanen, H | 1 |
| Laaksonen, MA | 1 |
| Reunanen, A | 1 |
| Männistö, S | 1 |
| Pérez, V | 1 |
| Sosti, V | 1 |
| Rubio, A | 1 |
| Barbanoj, M | 1 |
| Rodríguez-Alvarez, J | 1 |
| Kulisevsky, J | 1 |
| Ascherio, A | 1 |
| Zhang, SM | 1 |
| Hernán, MA | 1 |
| Kawachi, I | 1 |
| Colditz, GA | 1 |
| Speizer, FE | 1 |
| Willett, WC | 1 |
| Checkoway, H | 1 |
| Powers, K | 1 |
| Smith-Weller, T | 1 |
| Franklin, GM | 1 |
| Longstreth, WT | 1 |
| Swanson, PD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Parkinson's, Genes and Environment (PAGE) Study[NCT00367900] | 3,100 participants (Actual) | Observational | 2006-08-21 | Completed | |||
| Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)[NCT02008721] | Phase 3 | 92 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for caffeine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease.
Topics: Aged; Caffeine; Coffee; Dose-Response Relationship, Drug; Female; Humans; Male; Parkinson Disease, S | 2014 |
Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Caffeine; Central Nervo | 2003 |
14 other studies available for caffeine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Disease Models, Animal; Hypokinesia; Male; Mot | 2016 |
Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Agonists; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Dopamine a | 2009 |
Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Benzazepines; Caffeine; Corpus Str | 2009 |
Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caffeine; Corpus Striatum; Dopamine; Male; Mi | 2010 |
Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse.
Topics: Animals; Caffeine; Inflammation Mediators; Male; Maneb; Mice; Neuroprotective Agents; Nitric Oxide; | 2012 |
Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Brain; Caffeine; Conditioning, Operant; Dopamine; Dopami | 2004 |
Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Caffeine; Cell Count; Central Nervous | 2004 |
Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Cell Count; Dynorphins; Enkephalins; Globus Pa | 2005 |
Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, An | 2006 |
Sustained improvement of motor function in hemiparkinsonian rats chronically treated with low doses of caffeine or trihexyphenidyl.
Topics: Animals; Antiparkinson Agents; Brain; Caffeine; Central Nervous System Stimulants; Dose-Response Rel | 2007 |
Prospective study of coffee consumption and risk of Parkinson's disease.
Topics: Age Factors; Aged; Caffeine; Coffee; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hu | 2008 |
Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antip | 2007 |
Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.
Topics: Adult; Aged; Caffeine; Coffee; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disea | 2001 |
Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake.
Topics: Adult; Aged; Alcohol Drinking; Caffeine; Case-Control Studies; Coffee; Cola; Female; Humans; Male; M | 2002 |